Compare LYFT Inc (LYFT) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs McKesson Corporation — how do they compare? LYFT Inc trades at $16.23 (market cap $6.11B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 17.8× LYFT Inc's market cap, and McKesson Corporation pays a 0.4% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and McKesson Corporation for 74 Days on average.
| LYFT | MCK | |
|---|---|---|
Market Cap | $6.11B | $108.46B |
Volume | 13,504,560 | 712,607 |
Sector | Technology | Health |
52-Week High | $24.57 | $995.69 |
52-Week Low | $12.65 | $725.17 |
Typical Hold Time | 47 Days | 74 Days |
Enterprise Value | $5.57B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $15.60, down 1.02% with a bullish technical signal despite recent earnings misses. The company shows strong fundamental improvement with revenue growing from $4.1B in 2022 to $6.3B in 2025 and achieving profitability with $2.84B net income. Recent developments include European expansion and a $272.5M legal settlement. Valuation metrics appear attractive with P/E of 2.27 and P/S of 0.93, though EV/EBITDA remains elevated at 33.28.
Lyft presents a mixed outlook with strong cash flow growth and expanding operations balanced against competitive pressures and regulatory risks. The stock trades below analyst consensus target of $18.07, offering potential upside, but faces headwinds from driver classification lawsuits and market saturation concerns. Execution on European expansion and sustained profitability will be key catalysts for further appreciation.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
